Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine

NCT01592747 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT01592747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01592747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine
Lead sponsor
Forest Laboratories
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2012
Completion date
October 31, 2013
Enrollment
479 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

asperger syndrome, asperger's disorder, autism, autism spectrum disorders, autistic disorder, pervasive developmental disorder - not otherwise specified (pdd-nos)